Significance of Uracil/tegafur for Preventing Intravesical Recurrence of Non-muscle Invasive Urothelial Carcinoma of the Bladder

Overview

Journal Curr Urol

Specialty Urology

Date 2014 Jun 12

PMID 24917706

Citations 1

Authors

Ken-Ichi Harada

Hideaki Miyake

Tomoaki Terakawa

Masato Fujisawa

Affiliations

Soon will be listed here.

Abstract

Background: The objective of this study was to assess the role of uracil/tegafur (UFT) and its metabolite γ-butyrolactone (GBL), a potent inhibitor of angiogenesis, in the prevention of intravesical recurrence in patients with non-muscle invasive urothelial carcinoma of the bladder (NMIUCB).

Patients And Methods: This study included 48 patients with NMIUCB following complete transurethral resection who were randomly divided into 27 receiving UFT therapy (group A) and 21 without any adjuvant therapies (group B). Serum levels of GBL, vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor and interleukin-8 were measured.

Results: There was no significant difference in the intravesical recurrence-free survival between groups A and B. Despite the lack of significant differences in serum levels of vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor and interleukin-8, serum GBL in group A was significantly greater than in group B. Multivariate analysis identified tumor size as an independent predictor of intravesical recurrence irrespective of the other factors examined.

Conclusions: Despite the significant induction of GBL, adjuvant UFT therapy failed to show a preventive effect on intravesical recurrence of NMIUCB. Therefore, we should consider enhancing the anti-angiogenic effect of GBL using an alternative administration schedule of UFT.

Citing Articles

5-Fluorouracil-based adjuvant chemotherapy improves the clinical outcomes of patients with lymphovascular invasion of upper urinary tract cancer and low expression of dihydropyrimidine dehydrogenase.

Narimatsu T, Kambara T, Abe H, Uematsu T, Tokura Y, Suzuki I Oncol Lett. 2019; 17(5):4429-4436.

PMID: 30944635 PMC: 6444440. DOI: 10.3892/ol.2019.10086.

References

Shida K, Yamanaka H, Ito Y, Shimazaki J, ISAKA S, Yokokawa M . [Phase II study of UFT for malignant tumors of urinary organs]. Gan To Kagaku Ryoho. 1984; 11(6):1307-14. View

Whelan P . Bladder cancer--contemporary dilemmas in its management. Eur Urol. 2007; 53(1):24-6. DOI: 10.1016/j.eururo.2007.08.056. View

Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K . UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res. 1999; 5(8):2185-91. View

Nagai N, Mukai K, Hirata E, Jin H, Komatsu M, Yunokawa M . UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma. Med Oncol. 2007; 25(2):214-21. DOI: 10.1007/s12032-007-9023-1. View

Hisataki T, MIYAO N, Masumori N, Takahashi A, Yanase M, Itoh N . Risk factors for multiple intravesical recurrences of superficial bladder cancer. Urology. 2001; 58(6):935-9. DOI: 10.1016/s0090-4295(01)01435-2. View

Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S . Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology. 1999; 53(2):302-7. DOI: 10.1016/s0090-4295(98)00486-5. View

Shelley M, Mason M, Kynaston H . Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev. 2010; 36(3):195-205. DOI: 10.1016/j.ctrv.2009.12.005. View

Kubota Y, Hosaka M, Fukushima S, Kondo I . Prophylactic oral UFT therapy for superficial bladder cancer. Cancer. 1993; 71(5):1842-5. DOI: 10.1002/1097-0142(19930301)71:5<1842::aid-cncr2820710520>3.0.co;2-2. View

Agrawal U, Mishra A, Salgia P, Verma S, Mohanty N, Saxena S . Role of tumor suppressor and angiogenesis markers in prediction of recurrence of non muscle invasive bladder cancer. Pathol Oncol Res. 2010; 17(1):91-101. DOI: 10.1007/s12253-010-9287-1. View

10.

Miyake H, Hara I, Yamazaki H, Eto H . Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer. Oncol Rep. 2005; 14(3):673-6. View

11.

Wu A, Au J, Sadee W . Hydroxylated metabolies of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits. Cancer Res. 1978; 38(1):210-4. View

12.

Eissa S, Swellam M, Labib R, El-Zayat T, El Ahmady O . A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot. J Urol. 2009; 181(3):1353-60. DOI: 10.1016/j.juro.2008.10.102. View

13.

Stephen Jones J . Counter-point. Routine use of perioperative intravesical chemotherapy after TURBT: against. Urology. 2010; 76(4):797-8. DOI: 10.1016/j.urology.2010.06.046. View

14.

Taguchi T . Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU. Oncology. 1997; 54 Suppl 1:12-8. DOI: 10.1159/000227740. View

15.

Fujii S, Kitano S, Ikenaka K, Shirasaka T . Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gan. 1979; 70(2):209-14. View

16.

Kubota Y, Noguchi S, Hosaka M . UFT in bladder cancer. Oncology (Williston Park). 1999; 13(7 Suppl 3):112-5. View

17.

Oosterlinck W . The management of superficial bladder cancer. BJU Int. 2001; 87(2):135-40. DOI: 10.1046/j.1464-410x.2001.00948.x. View

18.

Dobruch J, Herr H . Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?. BJU Int. 2009; 104(2):170-4. DOI: 10.1111/j.1464-410X.2009.08654.x. View

19.

Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H . A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004; 350(17):1713-21. DOI: 10.1056/NEJMoa032792. View

20.

Sakai I, Miyake H, Harada K, Hara I, Inoue T, Fujisawa M . Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Int J Urol. 2006; 13(11):1389-92. DOI: 10.1111/j.1442-2042.2006.01562.x. View